Center for Basic Research, Division of Biotechnology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Anal Chem. 2011 Feb 1;83(3):708-18. doi: 10.1021/ac102075d. Epub 2010 Dec 21.
The current proof-of-principle study was aimed toward development of a novel multidimensional protein identification technology (MudPIT) approach for the in-depth proteome analysis of human serum derived from patients with benign prostate hyperplasia (BPH) using rational chromatographic design principles. This study constituted an extension of our published work relating to the identification and relative quantification of potential clinical biomarkers in BPH and prostate cancer (PCa) tissue specimens. The proposed MudPIT approach encompassed the use of three distinct yet complementary liquid chromatographic chemistries. High-pressure size-exclusion chromatography (SEC) was used for the prefractionation of serum proteins followed by their dialysis exchange and solution phase trypsin proteolysis. The tryptic peptides were then subjected to offline zwitterion-ion hydrophilic interaction chromatography (ZIC-HILIC) fractionation followed by their online analysis with reversed-phase nano-ultraperformance chromatography (RP-nUPLC) hyphenated to nanoelectrospray ionization-tandem mass spectrometry using an ion trap mass analyzer. For the spectral processing, the sequential use of the SpectrumMill, Scaffold, and InsPecT software tools was applied for the tryptic peptide product ion MS(2) spectral processing, false discovery rate (FDR) assessment, validation, and protein identification. This milestone serum analysis study allowed the confident identification of over 1955 proteins (p ≤ 0.05; FDR ≤ 5%) with a broad spectrum of biological and physicochemical properties including secreted, tissue-specific proteins spanning approximately 12 orders of magnitude as they occur in their native abundance levels in the serum matrix. Also encompassed in this proteome was the confident identification of 375 phosphoproteins (p ≤ 0.05; FDR ≤ 5%) with potential importance to cancer biology. To demonstrate the performance characteristics of this novel MudPIT approach, a comparison was made with the proteomes resulting from the immunodepletion of the high abundant albumin and IgG proteins with offline first dimensional tryptic peptide separation with both ZIC-HILIC and strong cation exchange (SCX) chromatography and their subsequent online RP-nUPLC-nESI-MS(2) analysis.
本初步验证研究旨在开发一种新型多维蛋白质鉴定技术(MudPIT),用于通过合理的色谱设计原则,对来自良性前列腺增生(BPH)患者的血清进行深入的蛋白质组分析。本研究是对我们已发表的关于 BPH 和前列腺癌(PCa)组织标本中潜在临床生物标志物的鉴定和相对定量工作的扩展。所提出的 MudPIT 方法包括使用三种不同但互补的液相色谱化学方法。高压尺寸排阻色谱(SEC)用于血清蛋白的预分级,然后进行透析交换和溶液相胰蛋白酶酶解。然后将胰蛋白酶肽进行离线两性离子-离子亲水性相互作用色谱(ZIC-HILIC)分级,然后与反相纳升级超高效液相色谱(RP-nUPLC)在线联用,使用离子阱质谱仪进行分析。对于光谱处理,应用了 SpectrumMill、Scaffold 和 InsPecT 软件工具的顺序使用,用于胰蛋白酶肽产物离子 MS(2)光谱处理、假发现率(FDR)评估、验证和蛋白质鉴定。这项里程碑式的血清分析研究使我们能够自信地鉴定出 1955 多种蛋白质(p ≤ 0.05;FDR ≤ 5%),这些蛋白质具有广泛的生物学和物理化学特性,包括分泌性、组织特异性蛋白质,跨越约 12 个数量级,它们以其在血清基质中的天然丰度水平存在。该蛋白质组还鉴定出 375 种磷酸化蛋白质(p ≤ 0.05;FDR ≤ 5%),这些蛋白质对癌症生物学具有潜在重要性。为了展示这种新型 MudPIT 方法的性能特点,我们将其与通过离线第一维胰蛋白酶肽分离与 ZIC-HILIC 和强阳离子交换(SCX)色谱进行免疫耗尽高丰度白蛋白和 IgG 蛋白后的蛋白质组进行了比较,并对其进行了后续的在线 RP-nUPLC-nESI-MS(2)分析。